ClinicalTrials.gg
CompletedNCT00319969Updated Sep 30, 2009

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

A Phase 2 interventional study of Amrubicin and Topotecan in Small Cell Lung Cancer, sponsored by Celgene Corporation. Completed at 47 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-30.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
12th of 17
76 · median 92
Started
2006
with 2 others
Phase 2
6 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2006, is one of 6 in phase 2, and was the 1st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • small cell lung cancer
  • amrubicin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of SCLC
  • Extensive disease (ED) at time of study entry
  • Response to platinum-based chemotherapy
  • Recurrent or progressive SCLC ≥90 days after completion of first-line therapy
  • At least 18 years of age
  • Performance Status of 0, 1, or 2
  • defined by criteria

    • Measurable disease: The presence of at least one measurable lesion. If only one lesion is present, the neoplastic nature of the disease site should be confirmed by histology and/or cytology.
    • Measurable lesion: Lesions that can be accurately measured in at least one dimension with the longest diameter ≥20mm using conventional techniques or ≥10mm using spiral CT scans.

CT (including spiral CT) scans and MRI are the preferred methods of measurement; however, chest x-rays are acceptable if the leions are clearly defined and surrounded by aerated lung. Clinically detected lesions will only be considered measurable when they are superficial (eg., skin nodules and palpable lymph nodes). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion is required.

  • Adequate organ function including the following:

    • Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) ≥1500 cells/μL, count ≥100,000 cells/μL and ≥9 g/dL
    • Hepatic: ≤1.5 X ; (ALT) and aspartate aminotransferase (AST) ≤3.0 X ULN
    • Renal: serum creatinine \<2.0mg/dL or calculated >60mL/min
    • Cardiac: (LVEF) ≥50%
  • Negative serum pregnancy test at the time of enrollment for women of . For men and women of child-producing potential, use of effective methods during the study.
  • Ability to understand the requirements of the study, provide written and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • Chest radiotherapy within the previous 28 days or other radiotherapy within the previous 14 days. Recovery from the acute toxic effects of radiation required prior to study enrollment. that have been previously irradiated must be enlarging to be considered target lesions. Prior radiation therapy allowed to \<25% of the bone marrow.
  • More than 1 prior chemotherapy regimen for SCLC
  • Prior anthracycline treatment
  • Participation in any drug study within 28 days prior to study entry
  • Patients with second primary (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence; prior low grade [Gleason score ≤6] localized prostate cancer is allowed)
  • Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
  • Symptomatic central nervous system . Patients with asymptomatic are allowed. The patient must be stable after radiotherapy for ≥2 weeks and off for ≥1 week.
  • History of interstitial lung disease or pulmonary fibrosis
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    1

    Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.

    Drug: Amrubicin

  • Active comparator
    2

    Topotecan 1.5mg/m\<2\> IV, days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.

    Drug: Topotecan

Interventions

  • Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.

  • Topotecan 1.5mg/m\<2\> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.

    Also known as: Hycamtin(R)

06

What researchers measure

Primary outcomes

  1. Objective tumor response rate

    Time frame: Until Disease Progression

Secondary outcomes

  1. Time to tumor progression

    Time frame: Until Disease Progression

  2. Progression free survival

    Time frame: Until death or disease progression

  3. Overall survival (median survival time; 1 year survival)

    Time frame: Until death

  4. Toxicity profile

    Time frame: Until 30 days after final dose

  5. Incidence of cumulative cardiomyopathy

    Time frame: Until end of study participation

  6. Regression of CNS metastases

    Time frame: Until disease progression

07

Study locations

47 sites
  • Birmingham Hematology & Oncology
    Birmingham, Alabama 35205, United States
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Alta Bates Medical Center - Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • Moores UCSD Cancer Center
    La Jolla, California 92093, United States
  • Rocky Mountain Cancer Center - Denver
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Center - Sky Ridge
    Lone Tree, Colorado 80124, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, PA
    Ocoee, Florida 34761, United States
  • John B. Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Cancer Care & Hematology Specialists of Chicago
    Niles, Illinois 60714, United States
  • Oncology & Hematology of Central Illinois
    Peoria, Illinois 61602, United States
  • Blessing Cancer Center
    Quincy, Illinois 62301, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Norton Healthcare - Louisville Oncology
    Louisville, Kentucky 40202, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building
    Baltimore, Maryland 21231, United States
  • Maryland Oncology Hematology, PA
    Columbia, Maryland 21044, United States
  • Alliance Hematology Oncology, PA - Carroll County Cancer Center
    Westminster, Maryland 21157, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Arch Medical Services - Center for Cancer Care & Research
    St Louis, Missouri 63141, United States
  • St. Joseph Oncology, Inc.
    St. Joseph, Missouri 64507, United States
  • Hematology/Oncology Consultants
    St. Louis, Missouri 63136, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • SUNY Upstate Medical University - Regional Oncology Center
    Syracuse, New York 13210, United States
  • Northwestern Carolina Oncology & Hematology
    Hickory, North Carolina 28602, United States
  • Cancer Centers of North Carolina
    Raleigh, North Carolina 27607, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Northwest Cancer Specialists
    Portland, Oregon 97225, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230-2510, United States
  • Texas Oncology, PA
    Dallas, Texas 75231, United States
  • Texas Oncology - Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology, PA
    Fort Worth, Texas 76104, United States
  • Alison Cancer Center
    Midland, Texas 79701, United States
  • West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer Care & Research Center
    Waco, Texas 76712, United States
  • Texas Oncology, PA - Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology & Hematology Associates of SW Virginia, Inc.
    Salem, Virginia 24153, United States
  • Puget Sound Cancer Center
    Seattle, Washington 98133, United States
  • Northwest Cancer Specialists - Vancouver Cancer Center
    Vancouver, Washington 98684, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Jul 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2006
First posted
Apr 27, 2006
Start
Apr 2006
Primary completionActual
Jul 2008
CompletionActual
Jan 2009
Results delay requested
Sep 28, 2009
Last update
Sep 30, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00319969
First posted
Apr 27, 2006
Start date
Apr 2006
Primary completion
Jul 2008
Completion
Jan 2009
Last update
Sep 30, 2009

Study contacts

Richard S Ungerleider, MD
study director · Theradex

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrubicin

Start the discussion